Novo Nordisk is chopping prices again for its popular obesity treatment Wegovy, but doctors say the expense will remain ...

Novo Nordisk’s stock tumbles after its oral GLP-1 drug failed to show much benefit over a placebo against Alzheimer’s.

Novo NordiskNVO reported early Monday that a pill version of its Ozempic failed to slow the progression of Alzheimer's in two ...

Novo Nordisk said on Monday that two late-stage trials testing an older oral version of its semaglutide drug failed to meet ...

Eli Lilly & Co. and Novo Nordisk A/S plan to start selling their popular obesity shots to employers through a new approach ...

Mangoceuticals later clarified in a separate statement that while it "has no direct contractual relationship with Eli Lilly ...

A Novo Nordisk challenge has driven Regen Doctors to voluntarily discontinue compounded semaglutide product claims, adding to ...

Both Eli Lilly and Novo Nordisk are denying a telehealth company’s claim of having struck partnerships with the two companies ...

The Danish drugmaker said it's cutting the price of Wegovy and Ozempic from $499 to $349 per month for some customers who buy ...

Studies from Novo Nordisk due early next month will give the strongest indication yet of whether blockbuster GLP-1 drugs - a ...

The findings suggest Zepbound may be a superior treatment for weight loss, helping obese or overweight patients lose 20.2% of their body weight, or roughly 50 pounds, on average after 72 weeks in the ...

Novo Nordisk and Eli Lilly reached deals to lower GLP-1 drug costs for Medicare and Medicaid patients under Trump’s new pricing initiative.